Skip to main content
. 2018 May 14;63(11):730–739. doi: 10.1177/0706743718777392

Table 2.

Summary Table of Meta-Analysis Prevalence Estimates of New Onset Of Dystonia, Akathisia, Parkinsonism, and Tremor for the 12 Antipsychotic Medications Reviewed.

Medication Dystonia
Prevalence % (95%CI);
Nr of studies and
participants;
I2 		Akathisia
Prevalence % (95%CI);
Nr of studies and
participants;
I2 		Parkinsonism
Prevalence % (95%CI);
Nr of studies and
participants;
I2 		Tremor
Prevalence % (95%CI);
Nr of studies and
participants;
I2
Amisulpride 6.4% (1.0 to 32.1);
3 studies,
218 participants;
I20		 11.3% (6.5 to 19.0);
9 studies,
744 participants;
I2 29.8		 10.3% (4.2- to 23.2);
8 studies,
646 participants;
I2 33.1		 4.4% (1.4 to 13.1);
7 studies,
632 participants;
I2 0
Aripiprazole 5.5% (4.0 to 7.4);
41 studies,
1715 participants;
I2 0		 8.5% (7.2 to 10.1);
70 studies,
6552 participants;
I2 0		 7.2% (4.7 to 10.9);
15 studies,
857 participants;
I2 0		 6.1% (4.8 to 7.7);
53 studies,
2397 participants;
I2 0
Asenapine 2.8% (1.2 to 6.0);
1 study,
217 participants;
I2 0		 Not reported 2.4% (0.2 to 25.6);
2 studies,
411 participants;
I2 0		 Not reported
Chlorpromazine 10.9% (5.2 to 21.3)
12 studies,
825 participants;
I2 41		 15.9% (12.4 to 20.2)
40 studies,
2087 participants;
I2 4.8		 21.1% (12.8 to 32.7)
20 studies,
910 participants;
I2 34		 18.4% (13.9 to 23.9)
29 studies,
1198 participants;
I2 22.9
Clozapine Not reported 7.9% (2.7 to 20.7);
4 studies,
657 participants;
I2 43.9		 3.7% (0.3 to 35.3);
2 studies,
162 participants;
I2 0		 0.2% (0 to 1.4);
1 study,
490 participants;
I2 0
Haloperidol 16.5% (11.7 to 22.8)
24 studies;
838 participants;
I2 7		 24.8% (20.4 to 29.9)
33 studies,
1278 participants;
I2 41		 22.6% (13.3 to 35.7)
6 studies,
255 participants;
I2 0		 22% (15.6 to 30)
23 studies,
727 participants;
I2 22.1
Olanzapine 1.6% (1.0 to 2.8);
10 studies,
2599 participants;
I2 10.5		 8.7% (6.9 to 10.9);
27 studies,
4569 participants;
I2 18.5		 8.1% (5.5 to 11.8);
15 studies,
2636 participants;
I2 37.5		 7.9% (4.2 to 14.4);
12 studies,
1366 participants;
I2 11.5
Paliperidone 2.4% (0.1 to 33.0);
2 studies,
226 participants;
I2 0		 3.3% (1.8 to 6.0);
6 studies,
1496 participants;
I2 0		 Not reported 2.7% (0.9 to 8.0);
7 studies,
1701 participants;
I2 0
Quetiapine 1.4% (0.7 to 2.8);
13 studies,
1642 participants;
I2 0		 5.2% (4.0 to 6.7);
35 studies,
3392 participants;
I2 0		 8.8% (4.6 to 16.3);
12 studies,
1585 participants;
I2 23.6		 6.0% (4.7 to 7.6);
20 studies,
1211 participants;
I2 0
Risperidone 5.0% (2.5 to 9.7);
11 studies,
1341 participants;
I2 22.5		 14.2% (11.4 to 17.6);
28 studies,
3263 participants;
I2 6.9		 12.1% (6.9 to 20.3);
16 studies,
1865 participants;
I2 51.2		 8.2% (6.1 to 11.1);
22 studies,
2699 participants;
I2 16.6
Sulpiride 15.3% (8.0 to 27.3);
6 studies,
146 participants;
I2 11.9		 16.4% (8.5 to 29.3);
8 studies,
211 participants;
I2 30.3		 29.3% (19.4 to 41.7);
7 studies,
193 participants;
I2 14.7		 28.2% (16.9 to 43.2);
4 studies,
93 participants;
I2 21.0
Ziprasidone 2.2% (1.0 to 4.8);
1 study,
271 participants;
I2 0		 8.3% (5.6 to 12.2);
6 studies,
832 participants;
I2 1		 10% (4.6 to 20.5);
1 study,
60 participants;
I2 0		 6.5 (2.2 to 17.8);
2 studies,
240 participants;
I2 0